Abstract
Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.
| Original language | English |
|---|---|
| Article number | 170076 |
| Journal | European Respiratory Review |
| Volume | 27 |
| Issue number | 147 |
| DOIs | |
| Publication status | Published - Mar 31 2018 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Best supportive care for idiopathic pulmonary fibrosis : Current gaps and future directions. / Ferrara, Giovanni; Luppi, Fabrizio; Birring, Surinder S.; Cerri, Stefania; Caminati, Antonella; Sköld, Magnus; Kreuter, Michael.
In: European Respiratory Review, Vol. 27, No. 147, 170076, 31.03.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Best supportive care for idiopathic pulmonary fibrosis
T2 - Current gaps and future directions
AU - Ferrara, Giovanni
AU - Luppi, Fabrizio
AU - Birring, Surinder S.
AU - Cerri, Stefania
AU - Caminati, Antonella
AU - Sköld, Magnus
AU - Kreuter, Michael
PY - 2018/3/31
Y1 - 2018/3/31
N2 - Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.
AB - Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.
UR - http://www.scopus.com/inward/record.url?scp=85041891339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041891339&partnerID=8YFLogxK
U2 - 10.1183/16000617.0076-2017
DO - 10.1183/16000617.0076-2017
M3 - Article
VL - 27
JO - European Respiratory Review
JF - European Respiratory Review
SN - 0905-9180
IS - 147
M1 - 170076
ER -